KR20070015598A - 융합 퀴놀린 유도체 및 이의 용도 - Google Patents
융합 퀴놀린 유도체 및 이의 용도 Download PDFInfo
- Publication number
- KR20070015598A KR20070015598A KR1020067024809A KR20067024809A KR20070015598A KR 20070015598 A KR20070015598 A KR 20070015598A KR 1020067024809 A KR1020067024809 A KR 1020067024809A KR 20067024809 A KR20067024809 A KR 20067024809A KR 20070015598 A KR20070015598 A KR 20070015598A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally
- carbonyl
- alkyl
- substituent
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *[C@]([C@@](CC1)[C@@]2N1C([C@@](CCCC1)[C@]1N)=O)Nc1c2cccc1 Chemical compound *[C@]([C@@](CC1)[C@@]2N1C([C@@](CCCC1)[C@]1N)=O)Nc1c2cccc1 0.000 description 12
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N NC(c1ccccc1)=O Chemical compound NC(c1ccccc1)=O KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- JKZXDXLLZQGLGW-YMNIQAILSA-N C1[C@@H](CNc2ccccc22)C2NC1 Chemical compound C1[C@@H](CNc2ccccc22)C2NC1 JKZXDXLLZQGLGW-YMNIQAILSA-N 0.000 description 1
- WKYAQOBNQMLPSA-HJNYFJLDSA-N C=C(CNC(OCc1ccccc1)=O)[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C=O Chemical compound C=C(CNC(OCc1ccccc1)=O)[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C=O WKYAQOBNQMLPSA-HJNYFJLDSA-N 0.000 description 1
- CHIBWDRNFGDLQS-UHFFFAOYSA-N C=NC(c1ccccc1)=O Chemical compound C=NC(c1ccccc1)=O CHIBWDRNFGDLQS-UHFFFAOYSA-N 0.000 description 1
- CKEISFOBIWCHHD-BBTUJRGHSA-N CC(C)(C)OC(N(CC[C@@]12C)[C@H]1c1ccccc1N[C@H]2c1c[s]cc1)=O Chemical compound CC(C)(C)OC(N(CC[C@@]12C)[C@H]1c1ccccc1N[C@H]2c1c[s]cc1)=O CKEISFOBIWCHHD-BBTUJRGHSA-N 0.000 description 1
- ITMKXEHYWXGWLP-UXJHKWJQSA-N CC(C)(CO)C(N[C@H](CCCC1)[C@H]1C(N1[C@H]2c3ccccc3N[C@@H](COC)[C@H]2CC1)=O)=O Chemical compound CC(C)(CO)C(N[C@H](CCCC1)[C@H]1C(N1[C@H]2c3ccccc3N[C@@H](COC)[C@H]2CC1)=O)=O ITMKXEHYWXGWLP-UXJHKWJQSA-N 0.000 description 1
- GJOKVXGJXOOPCN-SCFJQAPRSA-N CC/C=C\C=C(/C)\C(N)=O Chemical compound CC/C=C\C=C(/C)\C(N)=O GJOKVXGJXOOPCN-SCFJQAPRSA-N 0.000 description 1
- BHYDIFHAROFHIZ-NEFLSZPGSA-N CCC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(cc1)cc2c1[nH]c(C)n2)=O)=O Chemical compound CCC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(cc1)cc2c1[nH]c(C)n2)=O)=O BHYDIFHAROFHIZ-NEFLSZPGSA-N 0.000 description 1
- CSFGKUHYPXDCTC-QDSKXPNFSA-N CCOCCNC(NCCC(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1)=O)=O Chemical compound CCOCCNC(NCCC(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1)=O)=O CSFGKUHYPXDCTC-QDSKXPNFSA-N 0.000 description 1
- COHSCSRRGWZWQC-UHFFFAOYSA-N COC(C(CC1)(C2)C=CC1C2C(O)=O)=O Chemical compound COC(C(CC1)(C2)C=CC1C2C(O)=O)=O COHSCSRRGWZWQC-UHFFFAOYSA-N 0.000 description 1
- FFBPRHFKXVNLDV-UHFFFAOYSA-N COC(c1ccc(N2CCOCC2)nc1)=O Chemical compound COC(c1ccc(N2CCOCC2)nc1)=O FFBPRHFKXVNLDV-UHFFFAOYSA-N 0.000 description 1
- QHENDQUCLJVXMP-ALTAPNIQSA-N COCC([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(Nc1ccc(N2CCOCC2)nc1)=O)=O Chemical compound COCC([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(Nc1ccc(N2CCOCC2)nc1)=O)=O QHENDQUCLJVXMP-ALTAPNIQSA-N 0.000 description 1
- IFMCTPDDANMQQG-NSWSPSRDSA-N COCC([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(cccc1)c1C#N)=O)=O Chemical compound COCC([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(cccc1)c1C#N)=O)=O IFMCTPDDANMQQG-NSWSPSRDSA-N 0.000 description 1
- HHUWYKCNVAESJD-QJFAFGJBSA-N COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1C#[N]C(c(cc1)ccc1-c1cnc[o]1)=O)=O Chemical compound COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1C#[N]C(c(cc1)ccc1-c1cnc[o]1)=O)=O HHUWYKCNVAESJD-QJFAFGJBSA-N 0.000 description 1
- ZPMCTIGRAZYAFZ-DNGOPSCFSA-N COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(ccc(C#N)c1)c1F)=O)=O Chemical compound COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c(ccc(C#N)c1)c1F)=O)=O ZPMCTIGRAZYAFZ-DNGOPSCFSA-N 0.000 description 1
- KOFHYLXEWKAQSR-RMNHWBOMSA-N COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c1ccc(C(F)(F)F)cc1)=O)=O Chemical compound COC[C@@H]([C@H]1CC2)Nc3ccccc3[C@@H]1N2C([C@@H](CCCC1)[C@@H]1NC(c1ccc(C(F)(F)F)cc1)=O)=O KOFHYLXEWKAQSR-RMNHWBOMSA-N 0.000 description 1
- ICLITDDSHZESGC-UGSONSMCSA-N COc1ccc(C[n]2c(C([C@H](CC3)C4N3C([C@@H](CCCC3)[C@@H]3NC(c3ccccc3)=O)=O)Nc3c4cccc3)ncc2)cc1 Chemical compound COc1ccc(C[n]2c(C([C@H](CC3)C4N3C([C@@H](CCCC3)[C@@H]3NC(c3ccccc3)=O)=O)Nc3c4cccc3)ncc2)cc1 ICLITDDSHZESGC-UGSONSMCSA-N 0.000 description 1
- BDVZXZBKLDUQNY-WCQYABFASA-N C[C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O Chemical compound C[C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O BDVZXZBKLDUQNY-WCQYABFASA-N 0.000 description 1
- RCRPCQMNXDKVHN-NSCUHMNNSA-N C[n]1c(/C=C/C(O)=O)ncc1 Chemical compound C[n]1c(/C=C/C(O)=O)ncc1 RCRPCQMNXDKVHN-NSCUHMNNSA-N 0.000 description 1
- IFUVJKSAUSIFMQ-IWEOIBJYSA-N N#Cc(cc1)ccc1NC(N[C@H](CCCC1)[C@H]1C(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ncc[nH]1)=O)=O Chemical compound N#Cc(cc1)ccc1NC(N[C@H](CCCC1)[C@H]1C(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ncc[nH]1)=O)=O IFUVJKSAUSIFMQ-IWEOIBJYSA-N 0.000 description 1
- GUNZQDLCFRCGJM-LEDNWLKISA-N NC#CC(C(CC1)[C@H]2N1C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)=O)Nc1c2cccc1 Chemical compound NC#CC(C(CC1)[C@H]2N1C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)=O)Nc1c2cccc1 GUNZQDLCFRCGJM-LEDNWLKISA-N 0.000 description 1
- KTFCYSYAHAPWHS-WUMKDDEVSA-N NC[C@H]([C@@H]1CC2)Nc3ccccc3[C@H]1N2C(c1ccccc1NC(c1ccccc1)=O)=O Chemical compound NC[C@H]([C@@H]1CC2)Nc3ccccc3[C@H]1N2C(c1ccccc1NC(c1ccccc1)=O)=O KTFCYSYAHAPWHS-WUMKDDEVSA-N 0.000 description 1
- FKSDYOXDNDWDBU-CEWLAPEOSA-N O=C(C1CCCCC1)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1c[o]cc1 Chemical compound O=C(C1CCCCC1)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1c[o]cc1 FKSDYOXDNDWDBU-CEWLAPEOSA-N 0.000 description 1
- FCUMRPJIPIYBNM-KSEOMHKRSA-N O=C(C1CCCCC1)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1cnccc1 Chemical compound O=C(C1CCCCC1)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1cnccc1 FCUMRPJIPIYBNM-KSEOMHKRSA-N 0.000 description 1
- WZKNEKARHDVEKP-POLDFPFKSA-N O=C(CC1(CCCCC1)NC(Nc1ccccc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1ccccc1 Chemical compound O=C(CC1(CCCCC1)NC(Nc1ccccc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1ccccc1 WZKNEKARHDVEKP-POLDFPFKSA-N 0.000 description 1
- JHXJHZVKBNSRSG-UHFFFAOYSA-N O=C(CC1(CCCCC1)NC(c1ccccc1)=O)N(CC1)c2c1c(-c1ccccc1)nc1c2cccc1 Chemical compound O=C(CC1(CCCCC1)NC(c1ccccc1)=O)N(CC1)c2c1c(-c1ccccc1)nc1c2cccc1 JHXJHZVKBNSRSG-UHFFFAOYSA-N 0.000 description 1
- MWFDLJRYPHLHCQ-YLXXWHEUSA-N O=C(CCCN1CCOCC1)N[C@H](CCCC1)[C@H]1C(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1)=O Chemical compound O=C(CCCN1CCOCC1)N[C@H](CCCC1)[C@H]1C(N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1)=O MWFDLJRYPHLHCQ-YLXXWHEUSA-N 0.000 description 1
- SCYCIKACMGUDFT-AXDCVTDYSA-N O=C([C@@H](CCCC1)C1C#[N]C(NCCC[n]1cncc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1 Chemical compound O=C([C@@H](CCCC1)C1C#[N]C(NCCC[n]1cncc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1 SCYCIKACMGUDFT-AXDCVTDYSA-N 0.000 description 1
- BLJDQOVXSRVOPS-DQFDVREHSA-N O=C([C@@H](CCCC1)N1C(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccccc1 Chemical compound O=C([C@@H](CCCC1)N1C(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccccc1 BLJDQOVXSRVOPS-DQFDVREHSA-N 0.000 description 1
- LNUPXLMCBKKVIX-FNHDUMSZSA-N O=C([C@@H](CCCC1)[C@@H]1NC(NCCCN(CCC1)C1=O)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(NCCCN(CCC1)C1=O)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccccc1 LNUPXLMCBKKVIX-FNHDUMSZSA-N 0.000 description 1
- OCQFPWHOCWAGDX-SZIGWMETSA-N O=C([C@@H](CCCC1)[C@@H]1NC(Nc1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1c[s]cc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(Nc1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1c[s]cc1 OCQFPWHOCWAGDX-SZIGWMETSA-N 0.000 description 1
- RWBHTBYMOUOZNU-OZHIHCJWSA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccc(C(F)(F)F)cc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1ncc[nH]1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccc(C(F)(F)F)cc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1ncc[nH]1 RWBHTBYMOUOZNU-OZHIHCJWSA-N 0.000 description 1
- PXMGJRCOYPJTJR-WIOPSUGQSA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC1)c2c1c(-c1c[s]cc1)nc1c2cccc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC1)c2c1c(-c1c[s]cc1)nc1c2cccc1 PXMGJRCOYPJTJR-WIOPSUGQSA-N 0.000 description 1
- JYEWSPFFQWVQCD-HEFPDXONSA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1cnc[s]1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c(cccc1)c1N[C@H]2c1cnc[s]1 JYEWSPFFQWVQCD-HEFPDXONSA-N 0.000 description 1
- KRAYAMCXLXNOLT-RCOZLRPSSA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccn[n]1C(c1ccccc1)(c1ccccc1)c1ccccc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccn[n]1C(c1ccccc1)(c1ccccc1)c1ccccc1 KRAYAMCXLXNOLT-RCOZLRPSSA-N 0.000 description 1
- PRHJAROTLDDPPK-RCZACVGESA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccncc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@@H]12)[C@H]1c1ccccc1N[C@H]2c1ccncc1 PRHJAROTLDDPPK-RCZACVGESA-N 0.000 description 1
- KRAYAMCXLXNOLT-BTFJNRDASA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccn[n]1C(c1ccccc1)(c1ccccc1)c1ccccc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccn[n]1C(c1ccccc1)(c1ccccc1)c1ccccc1 KRAYAMCXLXNOLT-BTFJNRDASA-N 0.000 description 1
- PRHJAROTLDDPPK-VUSPDJBOSA-N O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccncc1 Chemical compound O=C([C@@H](CCCC1)[C@@H]1NC(c1ccccc1)=O)N(CC[C@H]12)[C@@H]1c(cccc1)c1N[C@@H]2c1ccncc1 PRHJAROTLDDPPK-VUSPDJBOSA-N 0.000 description 1
- FHLOXUAUWHXANE-JTQLQIEISA-N O=CNCC[C@@H](C1)CNc2c1cccc2 Chemical compound O=CNCC[C@@H](C1)CNc2c1cccc2 FHLOXUAUWHXANE-JTQLQIEISA-N 0.000 description 1
- FHLOXUAUWHXANE-JTQLQIEISA-M O=C[N-]CC[C@@H](C1)CNc2c1cccc2 Chemical compound O=C[N-]CC[C@@H](C1)CNc2c1cccc2 FHLOXUAUWHXANE-JTQLQIEISA-M 0.000 description 1
- WEQOFZFKUMWXAD-UHFFFAOYSA-N OC(CC1(CCCCC1)NC(Nc1ccccc1)=O)=O Chemical compound OC(CC1(CCCCC1)NC(Nc1ccccc1)=O)=O WEQOFZFKUMWXAD-UHFFFAOYSA-N 0.000 description 1
- PUANNVQABXUYKU-RYUDHWBXSA-N OC([C@@H](CCCC1)[C@H]1NC(c1ccccc1)=O)=O Chemical compound OC([C@@H](CCCC1)[C@H]1NC(c1ccccc1)=O)=O PUANNVQABXUYKU-RYUDHWBXSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N c1ccncc1 Chemical compound c1ccncc1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2004-00134705 | 2004-04-28 | ||
| JP2004134705 | 2004-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070015598A true KR20070015598A (ko) | 2007-02-05 |
Family
ID=34966886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067024809A Ceased KR20070015598A (ko) | 2004-04-28 | 2005-04-28 | 융합 퀴놀린 유도체 및 이의 용도 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US7592453B2 (https=) |
| EP (2) | EP1740584B9 (https=) |
| JP (2) | JP4361566B2 (https=) |
| KR (1) | KR20070015598A (https=) |
| CN (1) | CN1976932A (https=) |
| AT (1) | ATE416176T1 (https=) |
| AU (1) | AU2005238388B2 (https=) |
| BR (1) | BRPI0510365A (https=) |
| CA (1) | CA2565018A1 (https=) |
| CR (1) | CR8755A (https=) |
| CY (1) | CY1109222T1 (https=) |
| DE (1) | DE602005011424D1 (https=) |
| DK (1) | DK1740584T5 (https=) |
| ES (1) | ES2318483T4 (https=) |
| HR (1) | HRP20090121T5 (https=) |
| MX (1) | MXPA06012323A (https=) |
| MY (1) | MY143370A (https=) |
| NO (1) | NO20065494L (https=) |
| NZ (1) | NZ550983A (https=) |
| PL (1) | PL1740584T3 (https=) |
| PT (1) | PT1740584E (https=) |
| RS (1) | RS50756B (https=) |
| RU (1) | RU2384571C2 (https=) |
| SI (1) | SI1740584T1 (https=) |
| TW (1) | TW200540155A (https=) |
| WO (1) | WO2005105802A1 (https=) |
| ZA (1) | ZA200609261B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101493757B1 (ko) * | 2011-05-02 | 2015-02-16 | 르 라보레또레 쎄르비에르 | 4｛3〔시스-헥사하이드로시클로펜타〔ｃ〕피롤2（1ｈ）일〕프로폭시｝벤즈아미드와 아세틸콜린에스테라제 억제제의 회합체 및 이를 함유하는 약제 조성물 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070015598A (ko) * | 2004-04-28 | 2007-02-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 퀴놀린 유도체 및 이의 용도 |
| BRPI0510929A (pt) | 2004-06-18 | 2007-07-17 | Chiron Corp | derivados de n-(1-(1-benzil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil) benzamida e compostos relacionados como inibidores de proteìna de eixo de kinesin (ksp) para o tratamento de cáncer |
| JP2008517072A (ja) | 2004-10-20 | 2008-05-22 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良された阻害剤 |
| DE102005027170A1 (de) * | 2005-06-13 | 2006-12-14 | Merck Patent Gmbh | Substituierte Tetrahydrochinoline |
| GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
| WO2007074491A1 (en) * | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
| JP4509080B2 (ja) * | 2006-09-28 | 2010-07-21 | 信越化学工業株式会社 | シルセスキオキサン系化合物混合物及び加水分解性シラン化合物、その製造方法及びそれを用いたレジスト組成物並びにパターン形成方法及び基板の加工方法 |
| CA2672494A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| WO2008109991A1 (en) | 2007-03-09 | 2008-09-18 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| DE102007013856A1 (de) | 2007-03-20 | 2008-09-25 | Merck Patent Gmbh | Substituierte Tetrahydropyrrolochinoline |
| WO2008153027A1 (ja) * | 2007-06-11 | 2008-12-18 | Takeda Pharmaceutical Company Limited | ピロロキノリン誘導体およびその用途 |
| CA2694724C (en) * | 2007-08-01 | 2017-09-12 | University Health Network | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| AR069526A1 (es) | 2007-12-03 | 2010-01-27 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| US8592454B2 (en) | 2008-09-19 | 2013-11-26 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
| JP2011256110A (ja) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | ヘキサヒドロピロロキノリンの製造法 |
| WO2010038434A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | 光学活性なヘキサヒドロピロロキノリン類の製造法およびその中間体 |
| US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
| JP2013053070A (ja) * | 2009-11-06 | 2013-03-21 | Takeda Chem Ind Ltd | ジヒドロピロロキノリン誘導体 |
| EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
| EP2647638A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Substituted tricyclic compounds with activity towards ep1 receptors |
| CN105017266B (zh) * | 2015-07-17 | 2017-07-18 | 安徽农业大学 | 手性2‑芳基‑1,2,3,4‑四氢喹啉类化合物及其合成方法 |
| SG11201806416XA (en) | 2016-02-12 | 2018-08-30 | Astellas Pharma Inc | Tetrahydroisoquinoline derivatives |
| US11787795B2 (en) | 2016-11-01 | 2023-10-17 | President And Fellows Of Harvard College | Inhibitors of RNA guided nucleases and uses thereof |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| CA3157769A1 (en) * | 2019-11-27 | 2021-06-03 | Eiji IDEUE | Cycloalkyl urea derivative |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| US11738021B2 (en) | 2021-08-23 | 2023-08-29 | Ckp Therapeutics, Inc. | Composition and method for preventing, alleviating or treating cancer |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| CN114524811B (zh) * | 2022-03-16 | 2025-01-24 | 中国人民解放军军事科学院军事医学研究院 | Lxh0307、lxh0308作为基因编辑的小分子抑制剂及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
| EP0760819B1 (en) * | 1994-05-24 | 2000-07-19 | F. Hoffmann-La Roche Ag | Tricyclic dicarbonyl derivatives |
| IT1283171B1 (it) | 1996-03-01 | 1998-04-16 | Interdipartimentale Di Ricerca | Composti solubili antagonisti delle tachichinine loro preparazione e loro uso in composizioni farmaceutiche |
| GB0027701D0 (en) | 2000-11-13 | 2000-12-27 | Smithkline Beecham Spa | Novel compounds |
| EP1334089A1 (en) * | 2000-11-13 | 2003-08-13 | GlaxoSmithKline S.p.A. | Quinoline derivatives as nk-3 and nk-2 antagonists |
| DE60209362T2 (de) | 2001-04-11 | 2006-10-26 | Glaxosmithkline S.P.A. | 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten |
| JP2004134705A (ja) | 2002-10-15 | 2004-04-30 | Jiaotong Univ | 金属酸化膜半導体電界効果トランジスタおよびそのゲート構造 |
| KR20070015598A (ko) * | 2004-04-28 | 2007-02-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합 퀴놀린 유도체 및 이의 용도 |
-
2005
- 2005-04-28 KR KR1020067024809A patent/KR20070015598A/ko not_active Ceased
- 2005-04-28 MY MYPI20051875A patent/MY143370A/en unknown
- 2005-04-28 ES ES05738868T patent/ES2318483T4/es not_active Expired - Lifetime
- 2005-04-28 CA CA002565018A patent/CA2565018A1/en not_active Abandoned
- 2005-04-28 EP EP05738868A patent/EP1740584B9/en not_active Expired - Lifetime
- 2005-04-28 DK DK05738868.8T patent/DK1740584T5/da active
- 2005-04-28 AT AT05738868T patent/ATE416176T1/de active
- 2005-04-28 US US11/587,788 patent/US7592453B2/en not_active Expired - Fee Related
- 2005-04-28 EP EP08020921A patent/EP2080760A1/en not_active Withdrawn
- 2005-04-28 NZ NZ550983A patent/NZ550983A/en unknown
- 2005-04-28 WO PCT/JP2005/008558 patent/WO2005105802A1/en not_active Ceased
- 2005-04-28 PL PL05738868T patent/PL1740584T3/pl unknown
- 2005-04-28 MX MXPA06012323A patent/MXPA06012323A/es active IP Right Grant
- 2005-04-28 ZA ZA200609261A patent/ZA200609261B/xx unknown
- 2005-04-28 CN CNA200580021496XA patent/CN1976932A/zh active Pending
- 2005-04-28 DE DE602005011424T patent/DE602005011424D1/de not_active Expired - Lifetime
- 2005-04-28 HR HR20090121T patent/HRP20090121T5/hr unknown
- 2005-04-28 AU AU2005238388A patent/AU2005238388B2/en not_active Expired - Fee Related
- 2005-04-28 PT PT05738868T patent/PT1740584E/pt unknown
- 2005-04-28 SI SI200530595T patent/SI1740584T1/sl unknown
- 2005-04-28 RS RSP-2009/0085A patent/RS50756B/sr unknown
- 2005-04-28 BR BRPI0510365-7A patent/BRPI0510365A/pt not_active IP Right Cessation
- 2005-04-28 JP JP2006540061A patent/JP4361566B2/ja not_active Expired - Fee Related
- 2005-04-28 TW TW094113637A patent/TW200540155A/zh unknown
- 2005-04-28 RU RU2006141842/04A patent/RU2384571C2/ru not_active IP Right Cessation
-
2006
- 2006-11-17 CR CR8755A patent/CR8755A/es not_active Application Discontinuation
- 2006-11-28 NO NO20065494A patent/NO20065494L/no not_active Application Discontinuation
-
2009
- 2009-02-27 CY CY20091100236T patent/CY1109222T1/el unknown
- 2009-06-02 US US12/476,619 patent/US7973163B2/en not_active Expired - Fee Related
- 2009-06-02 US US12/476,626 patent/US7943770B2/en not_active Expired - Fee Related
- 2009-06-23 JP JP2009149204A patent/JP2009256362A/ja not_active Abandoned
- 2009-07-07 US US12/498,629 patent/US20090275568A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101493757B1 (ko) * | 2011-05-02 | 2015-02-16 | 르 라보레또레 쎄르비에르 | 4｛3〔시스-헥사하이드로시클로펜타〔ｃ〕피롤2（1ｈ）일〕프로폭시｝벤즈아미드와 아세틸콜린에스테라제 억제제의 회합체 및 이를 함유하는 약제 조성물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4361566B2 (ja) | 縮合キノリン誘導体およびその使用 | |
| US20110039893A1 (en) | Gsk-3beta inhibitor | |
| CN101928284A (zh) | 含氮杂环衍生物以及包含所述化合物作为活性成分的药物 | |
| TW201350475A (zh) | 用於組合療法之白三烯素生成之苯并二噁烷抑制劑 | |
| TW201350474A (zh) | 白三烯素生成之苯并二噁烷抑制劑 | |
| JP2023529884A (ja) | コラーゲン１翻訳阻害剤及びその使用方法 | |
| EP3022193B1 (en) | Inhibitors of leukotriene production | |
| US7795267B2 (en) | Bicyclic piperazine compound having TGR23 antagonistic activity | |
| JP2002348289A (ja) | ３環性複素環化合物、その製造法および用途 | |
| JP2002155084A (ja) | ３環性複素環化合物、その製造法およびその用途 | |
| JP2005306839A (ja) | 二環性ピペラジン化合物およびその用途 | |
| HK1099284B (en) | Fused quinoline derivative and use thereof | |
| CN101333185A (zh) | 含氮杂环衍生物以及包含所述化合物作为活性成分的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |